Abstract: A method of determining a device type and device properties includes receiving an input file including information related to a device, and identifying at least one layer set within the input file. The method further includes identifying at least one feature present in layer set. The method further includes analyzing a relationship between the at least one feature formed by the first layer and at least one feature formed by the second layer to determine at least one layer set relationship. The method further includes comparing the layer set relationship with at least one template layer set relationship. The method further includes determining the device type of the device based on the comparison between the layer set relationship and the template layer set relationship. The method further includes determining the device properties of the device based on the layer set relationship, the device type or the at least one feature.

Abstract: The present invention provides novel conjugates of camptothecin and camptothecin analogs with a linker and an HSA-binding moiety. The novel conjugates are prodrug forms of the camptothecin or camptothecin analogs and can be used to treat mammalian cell proliferative diseases, such as cancer.

Abstract: An electronic device may have a camera module. The camera module may capture images. The electronic device may include image processing circuitry that color corrects the images. The image processing circuitry may desaturate the images globally and/or spatially based on global and/or spatial noise levels of the image. The image processing circuitry may desaturate the images substantially without changing the hue of the images. The image processing circuitry may generate a color correction matrix with constant hue in real time and may color correct images in real time as the images are captured by the camera module.

Abstract: The present invention provides an improved process for preparing a narrow molecular weight distributed polytetramethylene ether glycol (PTMEG). The product polytetramethylene ether glycol has an increased number average molecular weight, a lowered polydispersity and a reduced molecular weight ratio when compared to the polytetramethylene ether glycol in the corresponding feedstock.

Abstract: The present invention provides an improved process and apparatus for alkanolysis of polytetramethylene ether diacetate to polytetraalkylene ether glycol in the presence of a C1 to C4 alkanol and an alkali or alkaline earth metal catalyst wherein the catalyst component of the product mixture comprising polytetraalkylene ether glycol, alkanol and catalyst, essentially free of the alkanol acetate by-product, e.g., methyl acetate is removed by contacting the mixture in the absence of added water with certain ion exchange resin at specified contact conditions.

Abstract: A process for synthesizing dodecane-1,12-diol, and by-products thereof, by the reduction of lauryl lactone produced from the oxidation of cyclododecanone.

Abstract: The present invention provides an improved process for converting a diester of polyether polyol, e.g., PTMEA, to the corresponding dihydroxy product, e.g., polytetramethylene ether glycol (PTMEG) continuously in a reaction zone, such as, for example, a reactive distillation system, for achieving virtually complete conversion of PTMEA to PTMEG, and recovery of PTMEG free of unreacted or unconverted PTMEA and alkanol ester by-product.

Abstract: The present invention relates to an improved process for manufacturing polyether and copolyether glycols by polymerization of a reaction mixture comprising at least one tetrahydrofuran or at least one tetrahydrofuran in the presence of a particular perfluorosulfonic acid resin catalyst comprising a copolymer of tetrafluoroethylene (TFE) or chlorotrifluoroethylene (CTFE) and a monomer of the formula CF2?CF—O—CF2—CF2—SO2F.

Abstract: A compound of formula: where Ar1, Ar2, X, R3, and m are as disclosed herein or a pharmaceutically acceptable salt thereof (a “Cycloheteroalkenyl Compound”); compositions comprising an effective amount of a Cycloheteroalkenyl Compound; and methods for treating or preventing pain, UI, an ulcer, IBD, IBS, an addictive disorder, Parkinson's disease, parkinsonism, anxiety, epilepsy, stroke, a seizure, a pruritic condition, psychosis, a cognitive disorder, a memory deficit, restricted brain function, Huntington's chorea, amyotrophic lateral sclerosis, dementia, retinopathy, a muscle spasm, a migraine, vomiting, dyskinesia, or depression in an animal comprising administering to an animal in need thereof an effective amount of a Cycloheteroalkenyl Compound are disclosed herein.

Abstract: A method for preventing pressure build-up across a catalyst separation in a polyether polyol reactor comprising the steps of feeding reactants that comprise a monomer or co-monomers to be polymerized to form the polyether polyol into a continuous feed reactor, flowing the product stream through a catalyst separation system within the reactor, wherein the catalyst separation system is comprised of a plurality of filters, wherein each filter comprises an outer surface and an inner surface defined by a plurality of spaced-apart elements, and wherein the distance between the spaced-apart elements is smaller than the minor dimension of the suspended catalyst and recovering the filtered polyether polyol product and catalyst fines from the reactor outlet.

Abstract: A kind of new compounds, and their pharmaceutically acceptable salts, and hydrates are disclosed. The pharmaceutical composition thereof is also provided. And also are the medical uses of the compounds, pharmaceutically acceptable salts, hydrates and the pharmaceutical composition for treating the TRPV1-mediate diseases.

Abstract: A compound of formula: wherein Ar1, A, R3, X, and m are as disclosed herein and Ar2 is a benzothiazolyl, benzooxazolyl, or benzoimidazolyl group or a pharmaceutically acceptable salt thereof (a “Benzoazolylpiperazine Compound”), compositions comprising a Benzoazolylpiperazine Compound, and methods for treating or preventing pain, UI, an ulcer, IBD, IBS, an addictive disorder, Parkinson's disease, parkinsonism, anxiety, epilepsy, stroke, a seizure, a pruritic condition, psychosis, a cognitive disorder, a memory deficit, restricted brain function, Huntington's chorea, amyotrophic lateral sclerosis, dementia, retinopathy, a muscle spasm, a migraine, vomiting, dyskinesia, or depression in an animal comprising administering to an animal in need thereof an effective amount of a Benzoazolylpiperazine Compound are disclosed.

Abstract: The present invention provides novel conjugates of camptothecin and camptothecin analogs with a linker and an HSA-binding moiety. The novel conjugates are prodrug forms of the camptothecin or camptothecin analogs and can be used to treat mammalian cell proliferative diseases, such as cancer.

Abstract: A compound of formula: wherein Ar1, Ar2, V, X, R3, R4, and m are as disclosed herein or a pharmaceutically acceptable salt thereof (a “Cyclo(hetero)alkenyl Compound”); compositions comprising an effective amount of a Cyclo(hetero)alkenyl Compound; and methods for treating or preventing, e.g., pain, UI, an ulcer, IBD, or IBS in an animal, comprising administering to an animal in need thereof an effective amount of a Cyclo(hetero)alkenyl Compound are disclosed herein.

Abstract: A compound of formula: where Ar1, Ar2, X, R3, and m are as disclosed herein or a pharmaceutically acceptable salt thereof (a “Cycloheteroalkenyl Compound”); compositions comprising an effective amount of a Cycloheteroalkenyl Compound; and methods for treating or preventing pain, UI, an ulcer, IBD, IBS, an addictive disorder, Parkinson's disease, parkinsonism, anxiety, epilepsy, stroke, a seizure, a pruritic condition, psychosis, a cognitive disorder, a memory deficit, restricted brain function, Huntington's chorea, amyotrophic lateral sclerosis, dementia, retinopathy, a muscle spasm, a migraine, vomiting, dyskinesia, or depression in an animal comprising administering to an animal in need thereof an effective amount of a Cycloheteroalkenyl Compound are disclosed herein.

Abstract: The present invention relates to a novel method for compatibilizing, i.e. improving miscibility of, otherwise immiscible organic materials highly useful in the fibers industry, as well as the compatibilized product of the method. These compatibilized products are stable in the liquid phase at temperatures ranging from about 40° C. to about 200° C. The method involves use of a glycol derived from polymerization of alkylene oxide and tetrahydrofuran, the alkylene oxide having from 2 to 4 carbon atoms, i.e. poly(tetramethylene-co-alkyleneether) glycol, in the mixture.

Abstract: The present invention provides a highly efficient process for manufacturing copolyether glycol having a mean molecular weight of from about 650 to about 5000 dalton by polymerization of tetrahydrofuran and at least one alkylene oxide in the presence of an acid catalyst and at least one compound containing reactive hydrogen atoms. More particularly, the invention relates to a process for manufacturing copolyether glycol which comprises recycle to the polymerization reaction step of at least a portion of the oligomeric cyclic ether which is co-produced with the copolyether glycol, said process exhibiting an Space Time Yield value of greater than about 0.9.

Abstract: Highly fluorinated ion-exchange polymers achieve dissolution in aqueous tetrahydrofuran at lower pressures and temperatures than in other solvents, with few or no side products being formed.

Abstract: A compound of formula: wherein Ar1, A, R3, x, and m are as disclosed herein and Ar2 is a benzothiazolyl, benzooxazolyl, or benzoimidazolyl group or a pharmaceutically acceptable salt thereof (a “Benzoazolylpiperazine Compound”), compositions comprising a Benzoazolylpiperazine Compound, and methods for treating or preventing pain, UI, an ulcer, IBD, IBS, an addictive disorder, Parkinson's disease, parkinsonism, anxiety, epilepsy, stroke, a seizure, a pruritic condition, psychosis, a cognitive disorder, a memory deficit, restricted brain function, Huntington's chorea, amyotrophic lateral sclerosis, dementia, retinopathy, a muscle spasm, a migraine, vomiting, dyskinesia, or depression in an animal comprising administering to an animal in need thereof an effective amount of a Benzoazolylpiperazine Compound are disclosed.

Abstract: A glove puppet manipulating system comprises a control module for generating control signals base on movements of human hand and a robot electrically connecting the control module installed inside a glove puppet. The robot has a body manipulating apparatus disposed on a foundation to manipulate the body of the glove puppet to rotate, a pair of hand manipulating apparatuses disposed on the body manipulating apparatus to manipulate the hands of the glove puppet to swivel, and a head manipulating apparatus interposed between the hand manipulating apparatuses on the body manipulating apparatus to manipulate the head of the glove puppet to nod.